Chargement en cours...
Preference for and adherence to oral phosphodiesterase-5 inhibitors in the treatment of erectile dysfunction
Sildenafil was the first orally administered phosphodiesterase-5 inhibitor approved for the treatment of erectile dysfunction. Its successful introduction into clinical practice was soon followed by the launch of two other phosphodiesterase-5 inhibitors: vardenafil and tadalafil. The plethora of cho...
Enregistré dans:
| Auteurs principaux: | , , , |
|---|---|
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Dove Medical Press
2008
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2770422/ https://ncbi.nlm.nih.gov/pubmed/19920956 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|